LBH-589 (Panobinostat, NVP-LBH589)

Panobinostat, a histone deacetylase inhibitor, is being tested in humans against cutaneous T cell lymphoma, prostate cancer, myelodysplastic syndromes, breast cancer, chronic myelogenous leukemia, and other types of malignant disease. Panobinostat inhibited histone deacetylase and induced acetylation of histone H3 and alpha-tubulin protein in human umbilical vein endothelial cells (HUVEC), which resulted in induction of G(2)-M cell cycle arrest and inhibition of HUVEC proliferation and viability. Panobinostat at noncytotoxic concentrations inhibited endothelial tube formation, Matrigel invasion, AKT activity, extracellular signal-regulated kinase 1/2 phosphorylation and chemokine receptor CXCR4 expression. It aslo reduced angiogenesis and PC-3 tumor growth in mice.\n\nSolubility:\nSoluble in DMSO at 200mg/ml; soluble in ethanol at 5mg/ml with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50uM buffers, serum, or other additives may increase or decrease the aqueous solubility.\n\nMelting Point:\n156-168C\n\nElemental Anaylsis:\nCalculated: \nC=70.09%\nH=6.77%\nN=11.68%\n\nStorage and Stability:\nMay be stored at RT for short-term only. Long-term storage is recommended at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts